Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04196010 · ClinicalTrials.gov registry record · Phase 1
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04196010 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 13 participants.
The verdict
NCT04196010, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of a chemotherapy regimen given by continuous intravenous infusion (CI-CLAM), and to see how well it works in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory) or other high-grade myeloid neoplasms. Drugs used in CI-CLAM include cladribine, cytarabine and mitoxantrone, and work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Continuous intravenous infusion involves giving drugs over a time duration of equal to or more than 24 hours. Giving CLAM via continuous infusion may result in fewer side effects and have similar effectiveness when compared to giving CLAM over the shorter standard amount of time.
Interventions
- DRUG Cladribine
- BIOLOGICAL Recombinant Granulocyte Colony-Stimulating Factor
- DRUG Cytarabine
- DRUG Mitoxantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-05-08 |
| Est. Completion | 2021-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04196010
The ClinicalTrials.gov registry entry for NCT04196010 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cladribine is the first listed.
NCT04196010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04196010 about?
NCT04196010 is a clinical study titled "Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms". This phase I trial studies the side effects and best dose of a chemotherapy regimen given by continuous intravenous infusion (CI-CLAM), and to see how well it works in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory) or other h...
What is the current status of trial NCT04196010?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-05-08. Estimated completion is 2021-10-13.
What interventions are being tested in trial NCT04196010?
The interventions under investigation include: Cladribine (DRUG), Recombinant Granulocyte Colony-Stimulating Factor (BIOLOGICAL), Cytarabine (DRUG), Mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT04196010?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.